» Articles » PMID: 34831017

Radiotherapy in the Treatment of Subcutaneous Melanoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Nov 27
PMID 34831017
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant melanoma frequently develops cutaneous and/or subcutaneous metastases during the course of the disease. These may present as non-nodal locoregional metastases (microsatellite, satellite, or in-transit) included in stage III or as distant metastases in stage IV. Their presentation is heterogeneous and associated with significant morbidity resulting from both disease-related functional damage and treatment side effects. The standard treatment is surgical excision, whereas local therapies or systemic therapies have a role when surgery is not indicated. Radiotherapy can be used in the local management of ITM, subcutaneous relapses, or distant metastases to provide symptom relief and prolong regional disease control. To increase the local response without increasing toxicity, the addition of hyperthermia and intralesional therapies to radiotherapy appear to be very promising. Boron neutron capture therapy, based on nuclear neutron capture and boron isotope fission reaction, could be an alternative to standard treatments, but its use in clinical practice is still limited. The potential benefit of combining radiotherapy with targeted therapies and immunotherapy has yet to be explored in this lesion setting. This review explores the role of radiotherapy in the treatment of cutaneous and subcutaneous lesions, its impact on outcomes, and its association with other treatment modalities.

Citing Articles

Proton Therapy in Uveal Melanoma.

Chan A, Lin H, Yacoub I, Chhabra A, Choi J, Simone 2nd C Cancers (Basel). 2024; 16(20).

PMID: 39456591 PMC: 11506608. DOI: 10.3390/cancers16203497.


Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors.

de Araujo Boleti A, Jacobowski A, Monteiro-Alfredo T, Pereira A, Oliva M, Maria D Molecules. 2024; 29(16).

PMID: 39202970 PMC: 11357276. DOI: 10.3390/molecules29163891.


Solid Lipid Nanoparticles Hydroquinone-Based for the Treatment of Melanoma: Efficacy and Safety Studies.

Trombino S, Malivindi R, Barbarossa G, Sole R, Curcio F, Cassano R Pharmaceutics. 2023; 15(5).

PMID: 37242616 PMC: 10222224. DOI: 10.3390/pharmaceutics15051375.

References
1.
Kang J, Demaria S, Formenti S . Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016; 4:51. PMC: 5028964. DOI: 10.1186/s40425-016-0156-7. View

2.
Formenti S, Demaria S . Systemic effects of local radiotherapy. Lancet Oncol. 2009; 10(7):718-26. PMC: 2782943. DOI: 10.1016/S1470-2045(09)70082-8. View

3.
Chaudhuri A, De-Groot C, Seel M, Jolly M, Cameron T . Treatment of regional cutaneous nodular metastases from melanoma using high-dose rate mould brachytherapy. J Med Imaging Radiat Oncol. 2011; 55(2):206-12. DOI: 10.1111/j.1754-9485.2011.02253.x. View

4.
Formenti S, Demaria S . Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012; 84(4):879-80. PMC: 3811126. DOI: 10.1016/j.ijrobp.2012.06.020. View

5.
Bentzen S, Overgaard J, Thames H, Overgaard M, Vejby Hansen P, von der Maase H . Clinical radiobiology of malignant melanoma. Radiother Oncol. 1989; 16(3):169-82. DOI: 10.1016/0167-8140(89)90017-0. View